Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. President & CEO Sean Saint reported an open-market sale of 16,872 shares of common stock at a weighted average price of $12.6071 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 420,937 shares directly.
BBNX submitted a Form 144 notice reporting the planned sale of Common Stock tied to Restricted Stock Units vesting under a registered plan, with an event date of 06/01/2026 and a filing date of 06/02/2026. The filing lists “Compensation for services rendered to Issuer” as the source.
BBNX submitted a Form 144 notice regarding proposed sales of Common Stock linked to Restricted Stock Units vesting under a registered plan. The filing lists 4,222 shares and identifies Morgan Stanley Smith Barney LLC as broker. The securities are described as compensation for services rendered to the issuer with dates anchored 06/01/2026 and 06/02/2026.
Beta Bionics reported a Form 144 notice by Michael Mensinger proposing the sale of 4,378 shares of Common Stock. The filing shows the securities relate to Restricted Stock Units vesting under a registered plan with a vesting date of 06/01/2026. The cover line lists a value of $55,994.62 and a reference share count of 44,561,695.
BBNX submitted a Form 144 reporting 6,676 shares of Common Stock tied to Restricted Stock Units that vested on 06/01/2026 as compensation. The filing also lists a prior sale of 1,428 shares on 03/02/2026 with proceeds shown as $17,652.37.
Beta Bionics, Inc. affiliate files a Form 144 proposing the resale of 16,872 shares of Common Stock. The filing lists an aggregate offering value of $215,792.88 and shows shares outstanding of 44,561,695 as of 06/02/2026. The shares are described as Restricted Stock Units vesting under a registered plan with a vesting date of 06/01/2026. The broker/dealer listed is Morgan Stanley Smith Barney LLC. The filing also reports a prior sale of 3,384 shares on 03/02/2026 for $41,831.65.
MICHEL GERARD J reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director MICHEL GERARD J received an equity grant of 16,965 shares of Common Stock on May 21, 2026. The award is structured as a restricted stock unit grant under the company’s 2025 Equity Incentive Plan and was issued at no cash cost, raising his direct holdings to 33,509 shares.
Beta Bionics, Inc. director Christy Jones reported both a stock award and a small share sale. On May 21, 2026, Jones received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, at no cash cost.
On the same date, Jones sold 1,998 common shares at $9.95 per share in an open‑market transaction. According to the filing, this sale was made pursuant to a Rule 10b5‑1 trading plan adopted on February 19, 2026, and Jones held 13,246 common shares directly after the sale.
Palasis Maria reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Maria Palasis received an equity award of 16,965 shares of Common Stock on May 21, 2026. The grant was issued at no cash cost as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, bringing her direct holdings to 29,397 shares.
Dearen Danny L. reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Danny L. Dearen reported receiving an equity grant in the form of restricted stock units. On May 21, 2026, he was awarded 16,965 shares of common stock at a stated price of $0.00 per share under the company’s 2025 Equity Incentive Plan. After this award, his direct holdings increased to 32,209 shares of common stock. This is a compensation-related grant rather than an open-market purchase or sale.